Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer

Fangyuan Zhou, Haiyang Gao, Luorui Shang, Jinxiao Li, Mengqi Zhang, Shuhan Wang, Runze Li, Lin Ye, Shenglan YangJournal of Experimental & Clinical Cancer Research 2023 · DOI

TL;DR

This study reveals that oridonin, a natural compound, combats colorectal cancer by activating TP53, which in turn represses TCF4. This TP53-mediated inhibition of TCF4 triggers endoplasmic reticulum (ER) stress, leading to cancer cell death. The findings highlight the TP53/TCF4 axis as a critical target for oridonin's anti-cancer effects.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant global health challenge, with increasing incidence and mortality rates. While traditional Chinese medicine offers promising therapeutic avenues, the precise molecular mechanisms behind their efficacy are often unclear. This paper investigates the anti-cancer effects of oridonin, a compound derived from Rabdosia rubescens, focusing on its role in inducing endoplasmic reticulum (ER) stress and its interplay with key molecular players like TP53 and TCF4 in CRC. The authors aim to elucidate how oridonin's therapeutic action is mediated at a molecular level, particularly concerning ER stress regulation, to provide a stronger scientific basis for its clinical application.

Methods

The researchers employed a multi-faceted approach to investigate oridonin's effects:

  • Cell proliferation, invasion, and migration assays: Standard techniques like CCK-8, EdU staining, Transwell, and wound healing assays were used to quantify these crucial cancer cell behaviors.
  • Molecular expression analysis: Western blot and qRT-PCR were utilized to measure protein and mRNA levels of key molecules involved in ER stress and signaling pathways.
  • Bioinformatic analysis: Position Weight Matrices (PWMs) software and the Gene Expression Omnibus (GEO) database were used to predict and analyze transcription factor binding and survival correlations.
  • ER stress visualization: Immunofluorescence (IF) and ER tracker-red staining allowed for the visualization of ER stress biomarkers and ER morphology.
  • Reactive Oxygen Species (ROS) and Calcium Ion (Ca²⁺) detection: Flow cytometry and fluorescent staining were employed to quantify intracellular ROS and Ca²⁺ levels.
  • In vivo studies: Athymic nude mice were used to establish subcutaneous xenograft models to assess oridonin's anti-tumor efficacy and its effects on tumor growth and histology.
  • Genetic manipulation: Stable overexpression and knockdown cell lines for TCF4 and TP53 were generated to dissect their specific roles.

Datasets

The study utilized publicly available datasets from the Gene Expression Omnibus (GEO) database, specifically accession numbers GSE14333, GSE17538, and GSE33114, for correlation analysis between gene expression and survival in cancer patients.

Key Insights and Ideas

  • Oridonin's dual action: Oridonin not only directly inhibits cancer cell proliferation, invasion, and migration but also does so by inducing ER stress. This suggests a multi-pronged attack on cancer cells.
  • TCF4 as a key regulator of ER stress: The research identifies TCF4 as a crucial factor in regulating ER stress. Its inhibition by oridonin is central to the observed anti-cancer effects.
  • TP53-TCF4 axis is critical: The study strongly implicates the TP53/TCF4 axis as a key mediator of oridonin's action. Oridonin activates TP53, which then represses TCF4, leading to enhanced ER stress.
  • ER stress is essential for oridonin's efficacy: Blocking ER stress with inhibitors significantly reduced oridonin's ability to kill cancer cells, underscoring the importance of this pathway.
  • Oridonin's safety profile: In vivo studies showed no significant histological damage to major organs in mice treated with oridonin at therapeutic doses, suggesting a favorable safety profile.

Key Results

  • Oridonin significantly inhibited the proliferation, invasion, and migration of colorectal cancer cells (RKO and LoVo) in a dose- and time-dependent manner.
  • Oridonin treatment led to increased expression of ER stress biomarkers (ATF4 and CHOP), altered ER morphology (swelling, vacuolation), and elevated intracellular ROS and Ca²⁺ levels.
  • TCF4 was identified as a key transcription factor regulating ER stress genes, and its expression was found to be higher in colorectal cancer cells compared to normal cells.
  • Oridonin treatment significantly reduced TCF4 expression and its downstream target genes (FYN, YOD1), while increasing CFTR expression.
  • Overexpression of TCF4 promoted tumor growth and invasion, while its knockdown had the opposite effect.
  • TP53 activation by oridonin was crucial for its anti-cancer effects; TP53 knockdown diminished oridonin's ability to inhibit tumor growth and ER stress.
  • In vivo studies demonstrated that oridonin significantly reduced tumor volume and weight in xenograft models, and this effect was dependent on the TP53/TCF4 axis.

Limitations and Future Work

The authors acknowledge that while their study provides a more solid scientific basis for oridonin's anti-cancer mechanism, further research is needed. They suggest that future pharmacological research and clinical trials are required to investigate the potential of oridonin in clinical applications and to evaluate its efficacy more comprehensively. Specifically, understanding the precise molecular interactions within the TP53/TCF4 axis and their downstream effects on ER stress pathways warrants further investigation.

Summary updated

Abstract

Oridonin upregulated TP53, inhibited TCF4 transactivation, and induced ER stress dysregulation in tumor cells, promoting colorectal cancer cell death. Therefore, TCF4 may be one of the important nodes for tumor cells to regulate ER stress and maintain protein synthesis homeostasis. And the inhibition of the TP53/TCF4 axis plays a key role in the anti-cancer effects of oridonin.
BibTeX
@article{zhou2023oridonin,
  author = {Fangyuan Zhou and Haiyang Gao and Luorui Shang and Jinxiao Li and Mengqi Zhang and Shuhan Wang and Runze Li and Lin Ye and Shenglan Yang},
  title = {{Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2023},
  doi = {10.1186/s13046-023-02702-4},
}
Figure